{
    "clinical_study": {
        "@rank": "24941", 
        "arm_group": [
            {
                "arm_group_label": "GC FLU inj.", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "GC3102C", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to demonstrate the immunological non-inferiority between GC3102C\n      and GC FLU inj. influenza vaccines by assessing geometric mean titers(GMTs) in healthy\n      adults"
        }, 
        "brief_title": "To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prophylaxis Against Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adults, 18 to <60 years old\n\n          -  Subjets willing to provide written informed consent and able to comply with the\n             requirements for the study\n\n        Exclusion Criteria:\n\n          -  Subjects with a history of hypersensitivity, especially anaphylactic reactions to\n             egg, egg proteins, chicken or components of vaccine such as gentamicin, gelatin, and\n             arginine\n\n          -  Subjects with a history of Guillain-Barr\u00e9 syndrome\n\n          -  Subjects with severe chronic diseases (e.g., cardiovascular diseases without\n             controllable hypertension, hemoglobinopathy, respiratory, metabolic, and renal\n             disorders) who are considered by the investigator to be ineligible for the study\n\n          -  Subjects previously treated with anti-coagulant therapy or hemophiliac patients who\n             may be at risk of severe hemorrhage after an intramuscular injection\n\n          -  Subjects who have had an acute febrile (at least 38.0\u00b0C) episode at some time during\n             the 72 hours before enrollment\n\n          -  Subjects who have received a vaccination within 7 days before enrollment or who are\n             scheduled for another vaccination (excluding the study vaccine) during the study\n\n          -  Immunocompromised subjects with immunodeficiency diseases or those who are receiving\n             immunosuppressive or immunomodulatory therapy, e.g., azathioprine, cyclosporin,\n             interferon, granulocyte-colony stimulating factor, tacrolimus, everolimus, sirolimus\n\n          -  Subjects who have received high-dose corticosteroids in the 3 months before\n             vaccination or who will be administered a cumulative dose of 700 mg of\n             corticosteroids during the study.  Inhaled, intranasal, and local application of\n             corticosteroids is permitted, regardless of dosage, and corticosteroids such as\n             prednisolone at a maximum dose of 15 mg/day are allowed\n\n          -  Subjects who have been administered immunoglobulins or blood-derived products 3\n             months before enrollment or who are scheduled for the administration during the study\n\n          -  Subjects who have received an influenza vaccine within 6 months of enrollment\n\n          -  A female subject who is pregnant or who is breast-feeding.  Subjects of childbearing\n             potential without an appropriate contraceptive measure within 30 days before\n             enrollment and who do not agree to use a clinically acceptable method of birth\n             control during the study (e.g., oral contraceptives, condom, diaphragm or\n             intrauterine device, or vasectomy of male partner)\n\n          -  Subjects who have participated in any other clinical trials within 30 days of the\n             administration of the study vaccine\n\n          -  Individuals with other clinically significant medical or psychological condition who\n             are considered by the investigator to be ineligible for the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750814", 
            "org_study_id": "GC3102C_P3"
        }, 
        "intervention": [
            {
                "arm_group_label": "GC3102C", 
                "intervention_name": "GC3102C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "GC FLU inj.", 
                "intervention_name": "GC FLU inj.", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 8, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Randomized, Double-blind, Multi-center Study to Compare the Immunological Efficacy and Safety of GC3102C With GC FLU Inj. Administered Intramuscularly in Healthy Adults", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Vietnam: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "GMT, using the Hemagglutination inhibition(HI) antibody titer", 
            "safety_issue": "Yes", 
            "time_frame": "Day 21"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750814"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of subjects achieving seroconversion", 
                "safety_issue": "No", 
                "time_frame": "Day 0 , Day 21"
            }, 
            {
                "measure": "Rate of subjects achieving seroprotection", 
                "safety_issue": "No", 
                "time_frame": "Day 21"
            }, 
            {
                "measure": "Number of Participants Reporting a Solicited Adverse Events After Vaccination", 
                "safety_issue": "Yes", 
                "time_frame": "Day 6"
            }, 
            {
                "measure": "Number of Participants Reporting a Unsolicited Adverse Events After Vaccination", 
                "safety_issue": "Yes", 
                "time_frame": "Day 21"
            }
        ], 
        "source": "Green Cross Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}